Bahar Tekin TAK, Firdevs Aysenur EKIZLER, Serkan CAY, Elif Hande Ozcan CETIN, Ozcan OZEKE, Serkan TOPALOGLU, Dursun ARAS, Mehmet Akif ERDOL, Kevser Gulcihan BALCI, Ahmet TEMIZHAN, Mehmet Serkan CETIN, Firat OZCAN

Kalp yetersizliğinde yeni bir prognostik belirteç: Pik mitral regurjitasyon velositesinin sol ventrikül çıkış yolu velosite zaman integraline oranı

Amaç: Sistemik vaskuler rezistans (SVR), kalp yetersizliğinde risk tahmini ve tedavi klavuzluğunda kullanışlıdır. Pik mitral regurgitasyon velositesinin (MRV) sol ventrikül çıkış yolu velosite zaman integraline (LVOT VTI) oranının SVR ile pozitif yönde korele olduğu gösterilmiştir. Bu çalışmada düşük ejeksiyon fraksiyonlu kalp yetersizliği (DEF-KY) hastalarında MRV/ LVOT VTI oranının bilinen prognostik belirteçlerle ilişkisi ve 1 yıllık ve uzun dönem birleşik son noktayi öngördürmedeki prognostik rolünü değerlendirmeyi amaçladık. Gereç ve Yöntemler: Prospektif olarak 72 DEF-KY hastası ve 10 sağlıklı kontrolü çalışmaya dahil ettik. Hastalar medyan 40.5 ay takip edildi. Birincil birileşik son nokta (BSN) mekanik dolaşım desteği, kalp transplantasyonu ve tüm nedenlere bağlı ölüm olarak tanımlandı. Bulgular: BSN(+) hastalarında daha yüksek MRV/LVOT VTI oranı saptandı (0.48±0.15 vs. 0.39±0.18 p=0.012). MRV/LVOT VTI oranı fonksiyonel sınıf (β=0.539, p=0

A new prognostic marker in failing heart: Peak mitral regurgitation velocity to left ventricular outflow tract time velocity integral ratio

Aim: Systemic vascular resistance (SVR) is useful for risk estimation and therapy guidance in HF. It has been shown that theratio of peak mitral regurgitation velocity (MRV) to left ventricular outflow tract velocity-time integral (LVOT VTI) correlatedpositively with SVR. We aimed to assess the association of MRV/LVOT VTI ratio with established prognostic markers andits prognostic role for predicting one year and long term composite end-points in patients with HF and reduced ejectionfraction (HFrEF).Material and Methods: We prospectively enrolled a total of 72 patients with HFrEF and 10 control subjects. Patients werefollowed up patients for median 40.5 months. Primary composite endpoint (CEP) was defined as any of these outcomesincluding requiring mechanical circulatory support, cardiac transplantation, and all-cause mortality.Results: CEP(+) patients had higher MRV/LVOT VTI ratio than others (0.48±0.15 vs. 0.39±0.18 p=0.012). MRV/LVOT VTIratio was positively correlated with functional status (β=0.539, p=0

PDF

___

1. Cotter G, Moshkovitz Y, Kaluski E et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003; 5: 443–51.
2. Abbas AE, David Fortuin F, Patel B, Moreno CA, Schiller NB, Lester SJ. Noninvasive measurement of systemic vascular resistance using Doppler echocardiography. Journal of the American Society of Echocardiography 2004; 17: 834–8.
3. Kumar A, Parrillo JE. Shock: Classification, Pathophysiology, and Approach to Management. Critical Care Medicine 2008: 379–422.
4. Hatle L, Angelsen BA, Tromsdal A. Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. Br Heart J 1981; 45: 157–65.
5. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol 1990; 66: 493–6.
6. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657–62.
7. Ommen SR, Nishimura RA, Appleton CP et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788–94.
8. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model. Circulation 2006; 113: 1424–33.
9. Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, Fraser AG, et al. Recommendations for a standardized report for adult transthoracic echocardiography: A report from the American Society of Echocardiography’s Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. Journal of the American Society of Echocardiography 2002; 15: 275–90.
10. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More “malignant” than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315–22.
11. Hastillo A, Willis H, Hess M. The heart as a target organ of immune injury. Current Problems in Cardiology 1991; 16: 381–442.
12. James TN. Myocarditis and cardiomyopathy. N Engl J Med 1983; 308: 39–41.
13. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988; 77: 721–30.
14. Mancia G. Neurohumoral activation in congestive heart failure. Am Heart J 1990; 120: 1532–7.
15. Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 2013;128.
16. Lund LH, Aaronson KD, Mancini DM. Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. The American Journal of Cardiology 2005; 95: 734–41.
17. Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G et al. Utility of the Seattle Heart Failure Model in Patients With Advanced Heart Failure. Journal of the American College of Cardiology 2009; 53: 334–42.